{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:08:05Z","timestamp":1792512485126,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40262-026-01654-0","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:26:16Z","timestamp":1780385176000},"page":"1087-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct04209049","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05564104","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mette J. F.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels-Peter","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene H. Hansen","family":"Duus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Kirkeby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Kup\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt W.","family":"Lauenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Svolgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Witten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"1654_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.13.632726","author":"MQ Ludwig","year":"2025","unstructured":"Ludwig MQ, Coester B, Gordian D, et al. A cross-species atlas of the dorsal vagal complex reveals neural mediators of cagrilintide\u2019s effects on energy balance. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.01.13.632726.","journal-title":"bioRxiv."},{"key":"1654_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","volume":"8","author":"CN Boyle","year":"2018","unstructured":"Boyle CN, Lutz TA, Le Foll C. Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018;8:203\u201310. https:\/\/doi.org\/10.1016\/j.molmet.2017.11.009.","journal-title":"Mol Metab"},{"issue":"15","key":"1654_CR3","doi-asserted-by":"publisher","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","volume":"64","author":"T Kruse","year":"2021","unstructured":"Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183\u201394. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00565.","journal-title":"J Med Chem"},{"issue":"10403","key":"1654_CR4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/s0140-6736(23)01163-7","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(23)01163-7.","journal-title":"Lancet"},{"issue":"3","key":"1654_CR5","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"DL Hay","year":"2015","unstructured":"Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564\u2013600. https:\/\/doi.org\/10.1124\/pr.115.010629.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1654_CR6","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1038\/s41467-025-58680-y","volume":"16","author":"J Cao","year":"2025","unstructured":"Cao J, Belousoff MJ, Johnson RM, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nat Commun. 2025;16(1):3389. https:\/\/doi.org\/10.1038\/s41467-025-58680-y.","journal-title":"Nat Commun"},{"issue":"10286","key":"1654_CR7","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/s0140-6736(21)00845-x","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736\u201348. https:\/\/doi.org\/10.1016\/s0140-6736(21)00845-x.","journal-title":"Lancet"},{"key":"1654_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502082","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2502082.","journal-title":"N Engl J Med"},{"key":"1654_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, Bl\u00fcher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2502081.","journal-title":"N Engl J Med"},{"issue":"10317","key":"1654_CR10","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/s0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(21)01751-7.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1654_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s00125-025-06497-1","volume":"68","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, Kuhlman AB, R\u00f8mer J, Pietil\u00e4inen KH, Tvermosegaard KB, Lau DCW. Efficacy and safety of cagrilintide 2.4 mg in adults with overweight\/obesity: data from REDEFINE 1. Diabetologia. 2025;68(Suppl 1):S1\u2013754. https:\/\/doi.org\/10.1007\/s00125-025-06497-1.","journal-title":"Diabetologia"},{"key":"1654_CR12","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. (CPMP\/EWP\/2339\/02). 2005. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf. Accessed 6 Apr 2025."},{"key":"1654_CR13","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function (EMA\/CHMP\/83874\/2014). 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf. Accessed 6 Apr 2025."},{"key":"1654_CR14","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function \u2013 study design, data analysis and impact on dosing and labeling. 2003. https:\/\/www.fda.gov\/media\/71311\/download. Accessed 6 Apr 2025."},{"key":"1654_CR15","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacokinetics in patients with impaired renal function \u2013 study design, data analysis, and impact on dosing. Guidance for industry. 2024. https:\/\/www.fda.gov\/media\/78573\/download. Accessed 6 Apr 2025."},{"key":"1654_CR16","unstructured":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3(1):1-150."},{"key":"1654_CR17","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Bioanalytical method validation. Guidance for industry. 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 6 Apr 2025."},{"key":"1654_CR18","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation (EMEA\/CHMP\/EWP\/192217\/2009 rev. 1 Corr. 2**). 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 6 Apr 2025."},{"issue":"12","key":"1654_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361. https:\/\/doi.org\/10.1007\/s00228-008-0553-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"1654_CR20","unstructured":"US Food and Drug Administration. SYMLIN\u00ae (pramlintide acetate) injection for subcutaneous use. Prescribing Information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021332s028lbl.pdf. Accessed 6 May 2025."},{"key":"1654_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgm005","author":"CS Cleeland","year":"2007","unstructured":"Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr. 2007;2007(37):16\u201321. https:\/\/doi.org\/10.1093\/jncimonographs\/lgm005.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"11","key":"1654_CR22","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","volume":"56","author":"TC Marbury","year":"2017","unstructured":"Marbury TC, Flint A, Jacobsen JB, Derving Karsb\u00f8l J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381\u201390. https:\/\/doi.org\/10.1007\/s40262-017-0528-2.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1654_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/dom.13186","volume":"20","author":"L Jensen","year":"2018","unstructured":"Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018;20(4):998\u20131005. https:\/\/doi.org\/10.1111\/dom.13186.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1654_CR24","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jcph.1131","volume":"58","author":"TA Baekdal","year":"2018","unstructured":"Baekdal TA, Thomsen M, Kup\u010dov\u00e1 V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314\u201323. https:\/\/doi.org\/10.1002\/jcph.1131.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1654_CR25","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","volume":"57","author":"C Granhall","year":"2018","unstructured":"Granhall C, S\u00f8ndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571\u201380. https:\/\/doi.org\/10.1007\/s40262-018-0649-2.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1654_CR26","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/hep4.1758","volume":"5","author":"L Hartl","year":"2021","unstructured":"Hartl L, Semmler G, Hofer BS, et al. COVID-19-related downscaling of in-hospital liver care decreased patient satisfaction and increased liver-related mortality. Hepatol Commun. 2021;5(10):1660\u201375. https:\/\/doi.org\/10.1002\/hep4.1758.","journal-title":"Hepatol Commun"},{"issue":"26","key":"1654_CR27","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.3748\/wjg.v29.i26.4166","volume":"29","author":"U Fedeli","year":"2023","unstructured":"Fedeli U, Barbiellini Amidei C, Casotto V, et al. Mortality from chronic liver disease: recent trends and impact of the COVID-19 pandemic. World J Gastroenterol. 2023;29(26):4166\u201373. https:\/\/doi.org\/10.3748\/wjg.v29.i26.4166.","journal-title":"World J Gastroenterol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01654-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:36:49Z","timestamp":1783748209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01654-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1654"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01654-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mette JF Nielsen, Helene H Hansen Duus, Katrine Kirkeby, Britt W Lauenborg, Benjamin Low and Louise Witten are employees and stockholders of Novo Nordisk A\/S. Niels-Peter Becker is a former employee of Novo Nordisk A\/S and a current employee of F. Hoffmann-La Roche Ltd. Viera Kup\u010dov\u00e1 has no conflicts of interest to report. Olivia Svolgaard is an employee of Novo Nordisk A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Relevant ethics committees approved both study protocols. All participants provided written, informed consent. Both studies were conducted in accordance with Good Clinical Practice, the Declaration of Helsinki and US Food and Drug Administration\/European Medicines Agency guidelines for studies in people with renal or hepatic impairment","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants provided written, informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate\/Publish"}},{"value":"An authorised researcher can request access to clinical trial study data by submitting a research proposal for review and approval by Novo Nordisk and an internal independent review panel. Requests are usually considered after the research is finished and the main results have been published. If the research supports a regulatory application, requests will be considered after the product, and its intended use are approved in both the EU and the USA. Participants\u2019 clinical data will be anonymised, following an approved internal process, before data are shared to external third parties. For details on how to request access to clinical data, visit novonordisk-trials.com.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Mette JF Nielsen, Britt W Lauenborg\u00a0and Viera Kup\u010dov\u00e1 contributed to the design, protocol and conduct of the studies. Olivia Svolgaard contributed to protocol development, conduct of the studies and closing the studies. Helene H Hansen Duus and Katrine Kirkeby were responsible for the statistical analyses. All authors were responsible for data interpretation. All authors had full access to study data, contributed to the drafting and revision of the manuscript and approved the manuscript for submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}